“…In addition, patients with increased cardiometabolic risks are always characterized by elevated serum ADA levels, and these cardiometabolic risks include higher BMI ( 35 ), increased TC ( 36 ), hypertension ( 16 ), atherosclerosis ( 13 ), thrombosis ( 14 ), coronary artery calcification ( 37 ) and T2D ( 38 ). Furthermore, in our previous studies and other previous studies, elevated serum ADA levels are not only involved in impaired pancreatic β-cell function in T2D ( 39 ) but also contribute to several diabetic complications, such as diabetic retinopathy ( 40 ), diabetic nephropathy ( 41 ), and prolonged heart QT interval in T2D ( 42 ). In our present study, serum ADA levels were observed to be positively correlated with ageing, higher SBP, longer diabetes duration, and increased levels of ALT, AST, GGT, CysC and HbA1c and negatively correlated with eGFR and insulin sensitivity index (IS-CP).…”